What question did this study set out to answer?

To investigate the amino acid profiles in post-mortem brain tissue from patients with Parkinson’s disease and Alzheimer’s disease.

March 6, 2026npj Parkinson s DiseaseOpen Access

Ultra-performance liquid chromatography–mass spectrometry analysis of post-mortem brain tissue reveals specific amino acid profile dysregulation in Parkinson’s disease and Alzheimer’s disease patients

View Full Paper

Ask AI

Bookmark

Authors

JGJacopo Gervasoni AMAnna Di MaioUniversity of Campania "Luigi Vanvitelli"MSMarcello SerraUniversity of Cagliari

Discussion

Member takes

Implication

Reveals specific amino acid profile changes in brain tissue of Parkinson’s and Alzheimer’s patients, indicating metabolic signatures of neurodegeneration.

Key Points

To investigate the amino acid profiles in post-mortem brain tissue from patients with Parkinson’s disease and Alzheimer’s disease.
Analyzed post-mortem brain samples using targeted ultra-performance liquid chromatography-mass spectrometry (UPLC-MS).
Sampled brain tissue from MPTP-intoxicated monkeys, both treated and untreated with L-DOPA, and from Parkinson’s disease patients at various Braak stages.
Measured amino acid levels in specific brain regions, including putamen and superior frontal gyrus.
Significant increases in glutamate, aspartate, GABA, phenylalanine, and branched-chain amino acids in untreated MPTP monkeys' putamen.
L-DOPA treatment further increased levels of glycine, threonine, and citrulline in the putamen.
Consistent serine upregulation was observed in caudate-putamen at Braak LB stages 3-4 and 6 in Parkinson’s disease patients.
Alzheimer’s disease samples showed marked amino acid increases in the superior frontal gyrus.

Cite This Study

Gervasoni et al. (2026) studied this question.

synapsesocial.com/papers/69aa6eb1531e4c4a9ff58fbb https://doi.org/10.1038/s41531-026-01306-x

View Full Paper

Ask AI

Bookmark

Implication

Reveals specific amino acid profile changes in brain tissue of Parkinson’s and Alzheimer’s patients, indicating metabolic signatures of neurodegeneration.

Ultra-performance liquid chromatography–mass spectrometry analysis of post-mortem brain tissue reveals specific amino acid profile dysregulation in Parkinson’s disease and Alzheimer’s disease patients

Discussion

Member takes

Implication

Key Points

Cite This Study

Ultra-performance liquid chromatography–mass spectrometry analysis of post-mortem brain tissue reveals specific amino acid profile dysregulation in Parkinson’s disease and Alzheimer’s disease patients

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider